 When we do renal cell carcinoma, or hepatocellular carcinoma, all you get is like this long list of TKI's. You could try seraphonib, regoraphonib, you could try cabozatinib, you could try latinvatinib. And we're just like, there's no real guidance, there's no precision stuff to say, okay, this one's a better chance or not. That is the hardest thing about aggressive tumors like hepatocellular carcinoma. Renal cells are a little slower. You're telling me I can volitionally choose to just put all of those single agents to help guide my therapies, like right now it's only toxicities. So oncology is basically I'm like, I don't know which one's going to work, but I can tell you the toxicities that we don't want and therefore we go that way. I can put that in and figure that out in how long a day, a week. It's one day to ship us the cells overnight via Federal Express. One day for us to apply the drug overnight in the dish and we give your oncologist the report back on day two, a two-day turnaround. To help guide things where I have no guidance, where it's like pick any one of these things. And we'll run 20 drugs. That is extraordinary.